Alvotech Inks $150M Licensing Deal with Lotus for Two Biosimilars
ALVO sits 47% above its 52-week low of $2.94.
Summary
Alvotech signed a licensing and commercialization agreement with Lotus Pharmaceutical covering AVT34 (proposed biosimilar to Imfinzi/durvalumab) and AVT87 (proposed biosimilar to Hemlibra/emicizumab). The deal includes up to $150 million in upfront and milestone payments plus ongoing supply revenue. In the U.S., Alvotech retains semi-exclusive rights to commercialize directly alongside Lotus, while Lotus gets exclusive rights in eight Asian markets. This is Alvotech's first direct U.S. commercialization opportunity, a strategic shift that could improve margins. The deal follows a series of capital raises and regulatory progress, including FDA acceptance of AVT16 and a recent H1 2026 loss. Watch for regulatory milestones on AVT34 and AVT87, though no specific dates were provided.
At the time of this announcement, ALVO was trading at $4.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $2.94 to $9.25. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.